← Leaderboards
Anastasia Khvorova
Rxi Pharmaceuticals Corporation
$18,868,535
Attributed
$24,512,346
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,512,346 · 10
By mechanism
R01$10,791,881 · 3
UH3$6,031,981 · 2
R35$2,657,475 · 1
UG3$2,473,416 · 1
S10$1,960,505 · 2
R43$597,088 · 1
Top collaborators
- Erik J Sontheimer6 shared
- Jonathan K Watts6 shared
- Scot A Wolfe6 shared
- Neil Aronin3 shared
Others in their field
Top investigators on “Small Interfering Rna”
- Randall J Bateman · Washington University$62,939,456
- Thomas William Geisbert · Boston University Medical Campus$30,074,519
- Judy Lieberman · Boston Children'S Hospital$24,680,725
- Michael Welch · Washington University$18,835,712
- Michael P Czech · Univ Of Massachusetts Med Sch Worcester$15,688,365
- Gary B. Ruvkun · Massachusetts General Hospital$15,618,516
Research focus
Small Interfering RnaOligonucleotidesChemistryIn VivoBaseTissuesVariantToxic EffectMessenger RnaAntisense OligonucleotidesRna InterferenceGenesSpecificityAnimal ModelPropertyProteinsGene SilencingKidneyMetabolicModificationMedicalTechnologyMediatingPrevent
Grant awards (37)
Expanding the Chemical Diversity of Therapeutic Oligonucleotides$688,196
R01 · FY2025 · NS · contact PI
Chemical engineering of therapeutic RNAs for extrahepatic delivery$460,625
R35 · FY2025 · GM · contact PI
High-throughput Oligonucleotide Production System$1,397,364
S10 · FY2024 · OD · contact PI
Expanding the Chemical Diversity of Therapeutic Oligonucleotides$667,550
R01 · FY2024 · NS · contact PI
Expanding the Chemical Diversity of Therapeutic Oligonucleotides$688,196
R01 · FY2023 · NS · contact PI
Chemical engineering of therapeutic RNAs for extrahepatic delivery$435,500
R35 · FY2023 · GM · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$1,370,507
UH3 · FY2022 · TR
Chemical engineering of therapeutic RNAs for extrahepatic delivery$435,500
R35 · FY2022 · GM · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$333,834
UH3 · FY2022 · TR
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$1,386,695
UH3 · FY2021 · TR
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders$659,650
R01 · FY2021 · NS · contact PI
Chemical engineering of therapeutic RNAs for extrahepatic delivery$435,500
R35 · FY2021 · GM · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$819,031
UG3 · FY2020 · TR
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia$667,335
R01 · FY2020 · HD · contact PI
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders$659,650
R01 · FY2020 · NS · contact PI
Chemical engineering of therapeutic RNAs for extrahepatic delivery$435,500
R35 · FY2020 · GM · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$828,360
UG3 · FY2019 · TR
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia$687,791
R01 · FY2019 · HD · contact PI
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders$664,751
R01 · FY2019 · NS · contact PI
Chemical engineering of therapeutic RNAs for extrahepatic delivery$454,850
R35 · FY2019 · GM · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$826,025
UG3 · FY2018 · TR
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia$680,821
R01 · FY2018 · HD · contact PI
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders$664,751
R01 · FY2018 · NS · contact PI
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAs$148,651
R01 · FY2018 · GM · contact PI
Exosome based therapeutics in Huntington's disease$972,449
UH3 · FY2017 · TR
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia$685,210
R01 · FY2017 · HD · contact PI
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders$664,751
R01 · FY2017 · NS · contact PI
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAs$464,548
R01 · FY2017 · GM · contact PI
Exosome based therapeutics in Huntington's disease$980,438
UH3 · FY2016 · TR
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia$706,386
R01 · FY2016 · HD · contact PI
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAs$464,548
R01 · FY2016 · GM · contact PI
Exosome based therapeutics in Huntington's disease$988,058
UH3 · FY2015 · TR
Mid-Scale RNA Synthesis, Purification and Quality Control System$563,141
S10 · FY2015 · OD · contact PI
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAs$464,548
R01 · FY2015 · GM · contact PI
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAs$464,548
R01 · FY2014 · GM · contact PI
Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders$298,544
R43 · FY2011 · AI · contact PI
Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders$298,544
R43 · FY2010 · AI · contact PI